Glenmark Recalls Generic Of Singulair Asthma Drug In Smelly Bottles
This article was originally published in PharmAsia News
Glenmark Pharmaceuticals recalled its allergy and asthma drug following reports of 29 batches of the bottled treatment emitted musty odors of preservative chemicals.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.